시스플라틴 유도 신장 독성에 대한 반하사심탕 추출물의 방어효과
Inhibitory Effects of Banhasasim-tang Extracts on Cisplatin-induced Nephrotoxicity in Mouse Model
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
In this study, Banhasasim-tang extracts (BSTE) have an inhibitory effects on cisplatin-induced nephrotoxicity in mouse model. Cisplatin is the most widely used anticancer drug for treatment of various cancer. However, cisplatin treatment to cancer patients leads to many side effects such as nephrotoxicity and body weight decrease. We hypothesize that BSTE improve the cisplatin-induced side effects in mouse model. We found that BSTE administration protected tubular injury by cisplatin in mouse model. BSTE also inhibited increase of creatinine and BUN induced by cisplatin injection in serum. Collectively, our data suggest that BSTE could be a therapeutic agent for reducing kidney injury induced by cisplatin treatment in cancer patients.
Abstract
In this study, Banhasasim-tang extracts (BSTE) have an inhibitory effects on cisplatin-induced nephrotoxicity in mouse model. Cisplatin is the most widely used anticancer drug for treatment of various cancer. However, cisplatin treatment to cancer patients leads to many side effects such as nephrotoxicity and body weight decrease. We hypothesize that BSTE improve the cisplatin-induced side effects in mouse model. We found that BSTE administration protected tubular injury by cisplatin in mouse model. BSTE also inhibited increase of creatinine and BUN induced by cisplatin injection in serum. Collectively, our data suggest that BSTE could be a therapeutic agent for reducing kidney injury induced by cisplatin treatment in cancer patients.
참고문헌 (17)
- Krarup-Hansen A, "Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies", Brain, 130, pp.1076~1088 (2007)
- Pabla N, "Cisplatin nephrotoxicity: mechanisms and strategies", Kidney Int, 73, pp.994~1007 (2008)
- Kelland L, "The resurgence of platinum-based cancer chemotherapy", Nat. Rev. Cancer, 7, pp.573~584 (2007)
- Dasari S, "Cisplatin in cancer therapy: molecular mechanisms of action", Eur. J. Pharmacol, 740, pp.364~378 (2014)
- Nicolao P, "Neurological toxicity of ifosfamide", Oncology, 65, pp.11~16 (2003)
- 주성민, "Cisplatin과 보정방암탕에 의한 백서 사구체 혈관사이세포의 세포사멸 기전 연구", 동의생리병리학회지, 27(1), pp.43~48 (2013), 한의병리학회
- 김대근, "Cisplatin의 신장독성에 대한 영지추출물 복합제재의 보호효과", 동의생리병리학회지, 17(2), pp.316~325 (2003), 한의병리학회
- 김재영, "토끼에서 cisplatin에 의해 유도된 급성 신부전시 산조인 추출물의 효과", 생명과학회지, 24(7), pp.777~783 (2014), 한국생명과학회
- Zhang ZJ, "Shanghanzabinglun, Han dinasty", pp.112~ (1993), Daesungmunhwasa
- Heo, J., "Donguibogam", pp.397~ (2007), Namsandang
- Ozols RF, "High-dose cisplatin in hypertonic saline", Ann. Intern. Med, 100, pp.19~24 (1984)
- Gandara DR, "Evaluation of cisplatin dose intensity: current status and future prospects", Anticancer Res, 9, pp.1121~1128 (1989)
- Oriana S, "A preliminary clinical experience with reduced glutathione as protector against cisplatintoxicity", Tumori, 73, pp.337~340 (1987)
- Aoyama T, "Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis", Cancer Chemother. Pharmacol, 73, pp.1047~1054 (2014)
- Yamashita T1, "A traditional Japanese medicine-- Hangeshashinto (TJ-14)--alleviates chemoradiation-induced mucositis and improves rates of treatment completion", Support. Care Cancer, 23(1), pp.29~35 (2015)
- Storck M, "Production of proinflammatory cytokines and adhesion molecules in exvivo xenogeneic kidney perfusion", Transplant International, 7, pp.647~649 (1994)
- Ramesh G, "TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity", Journal of Clinical Investigation, 110, pp.835~842 (2002)